Bruell, S. http://orcid.org/0000-0002-8419-6711
Nicholls, K. M.
Hewitson, T. D. http://orcid.org/0000-0002-1994-2423
Talbot, A. S.
Holt, S. G.
Smith, E. R.
Ruderman, I.
Funding for this research was provided by:
University of Melbourne
Article History
Received: 24 October 2021
Accepted: 3 May 2022
First Online: 16 May 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the <i>Melbourne Health Human Research Ethics Committee (#2012.141 & #2001.144).</i>
: Informed consent was obtained from all individual participants included in the study.
: All authors read and approved the final manuscript for publication.
: ERS owns stock in Calciscon AG, which commercializes the T<sub>50</sub> test and reports research funding from Amgen and Sanofi, outside the submitted work. SB reports no relevant conflicts of interest. KMN reports no relevant conflicts of interest. TDH reports no relevant conflicts of interest. AST reports no relevant conflicts of interest. SGH reports no relevant conflicts of interest. IR reports no relevant conflicts of interest.